CorMedix up after FY revenue guidance raise

CorMedix

12/11/2025 13:19

** Shares of biopharma firm CorMedix CRMD.O rise 6% to $11.86 premarket

** Co lifts FY revenue guidance to $390 mln-$410 mln from prior guidance of at least $375 million

** CRMD also reports quarterly revenue and net income better than expectations

** Co says revenue driven by sales of DefenCath - co's lead product

** Seven of seven brokerages rate the stock "buy" or higher; their median PT is $20- LSEG

** Up to last close, stock up 38.2% YTD

 (Reporting by Avinash P in Bengaluru)

 ((Avinash.P@thomsonreuters.com;))